

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit
<b>First Implementation Date:</b>	November 18, 2010
<b>Proposed Date:</b>	September 16, 2021
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of serotonin-norepinephrine reuptake inhibitor (SNRI) agents

**Why Issue Selected:** MO HealthNet will assess the usage of SNRI agents in the pharmacy program with a primary goal of patient safety. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and without a clinical edit it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. By using medical evidence guidelines, this clinical edit can flag potentially dangerous duplicate and high dose therapy for SNRI agents. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

## Program-Specific Information:

Date Range FFS 7-1-2020 to 6-30-2021				
Generic Equivalent	Drug Description	Claims	Spend	Avg Spend per Claim
DESVENLAFAXINE	DESVENLAFAXINE ER 50 MG TAB	82	\$11,616.36	\$141.66
	DESVENLAFAXINE ER 100 MG TAB	134	\$18,127.65	\$135.28
	PRISTIQ ER 25 MG TABLET	1,378	\$50,723.02	\$36.81
	PRISTIQ ER 50 MG TABLET	5,741	\$199,996.39	\$34.84
	PRISTIQ ER 100 MG TABLET	6,585	\$235,717.48	\$35.80
DULOXETINE	CYMBALTA 20 MG CAPSULE	6,581	\$139,934.27	\$21.26
	CYMBALTA 30 MG CAPSULE	36,948	\$777,763.48	\$21.05
	CYMBALTA 60 MG CAPSULE	66,234	\$1,389,378.39	\$20.98
	DRIZALMA SPRINKLE DR 20 MG CAP	3	\$833.69	\$277.90
	DRIZALMA SPRINKLE DR 30 MG CAP	28	\$2,576.82	\$92.03
	DRIZALMA SPRINKLE DR 40 MG CAP	0	-	-
	DRIZALMA SPRINKLE DR 60 MG CAP	57	\$10,100.10	\$177.19
	IRENKA DR 40 MG CAPSULE	677	\$62,420.98	\$92.20
LEVOMILNACIPRAN	FETZIMA ER 20 MG CAPSULE	316	\$156,789.78	\$496.17
	FETZIMA ER 40 MG CAPSULE	578	\$236,493.37	\$409.16
	FETZIMA ER 80 MG CAPSULE	548	\$203,890.35	\$372.06
	FETZIMA ER 120 MG CAPSULE	691	\$249,347.43	\$360.85
MILNACIPRAN	FETZIMA 20-40 MG TITRATION PAK	17	\$5,894.20	\$346.72
	SAVELLA 12.5 MG TABLET	17	\$4,311.61	\$253.62
	SAVELLA 25 MG TABLET	141	\$59,561.09	\$422.42
	SAVELLA 50 MG TABLET	602	\$193,913.81	\$322.12

	SAVELLA 100 MG TABLET	620	\$209,582.27	\$338.04
	SAVELLA TITRATION PACK	46	\$15,509.91	\$337.17
VENLAFAXINE	EFFEXOR 25 MG TABLET	369	\$7,598.65	\$20.59
	EFFEXOR 37.5MG TABLET	1,707	\$34,148.33	\$20.00
	EFFEXOR 50MG TABLET	422	\$9,090.21	\$21.54
	EFFEXOR 75MG TABLET	3,166	\$65,019.29	\$20.54
	EFFEXOR 100MG TABLET	966	\$21,682.90	\$22.45
VENLAFAXINE ER	VENLAFAXINE HCL ER 37.5 MG TAB	416	\$58,124.60	\$139.72
	VENLAFAXINE HCL ER 75 MG TAB	772	\$103,589.38	\$134.18
	VENLAFAXINE HCL ER 150 MG TAB	1,292	\$143,022.48	\$110.70
	VENLAFAXINE HCL ER 225 MG TAB	6,007	\$921,361.10	\$153.38
	EFFEXOR XR 37.5 MG CAPSULE	8,407	\$160,618.02	\$19.11
	EFFEXOR XR 75 MG CAPSULE	22,015	\$422,984.11	\$19.21
	EFFEXOR XR 150 MG CAPSULE	26,916	\$570,007.16	\$21.18
<b>Total</b>		<b>200,479</b>	<b>\$6,751,728.68</b>	<b>\$33.68</b>

Type of Criteria: ☐ Increased risk of ADE  
☒ Appropriate Indications

☐ Preferred Drug List  
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Serotonin-norepinephrine reuptake inhibitor (SNRI) agents
- Age range: All appropriate MO HealthNet participants aged 5 years and older

## Approval Criteria

- Participant aged 5 years or older **AND**
- Documented compliance to current SNRI therapy regimen (90 days in the past 120 days) **OR**
- Documented appropriate diagnosis required for:
  - Participants < 18 years of age **OR**
  - Participants < 26 years of age who are also enrolled in foster care
- **For diagnosis of major depressive disorder: all SNRI agents except Savella**
- For diagnosis of fibromyalgia: **duloxetine agents** or Savella only
- For diagnosis of chronic musculoskeletal pain or diabetic peripheral neuropathic pain: duloxetine agents only
- **For diagnosis of generalized anxiety disorder: duloxetine or venlafaxine agents only**
- **For diagnosis of social anxiety disorder, panic disorder, or migraine: venlafaxine agents only**
- **For Fetzima: documented therapeutic trial of generic Cymbalta or Effexor XR**
- **For venlafaxine HCL ER tablets and desvenlafaxine ER tablets: documented reason why participant cannot utilize generic Effexor XR capsules**

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosage limits (see Appendix A)
- Participants < 18 years of age: history of > 2 SNRI agents for more than 30 days in the past 90 days
- Participants ≥ 18 years of age: history of > 2 SNRI agents for more than 60 days in the past 90 days
- Participant is on more than one SSRI agent and one SNRI agent concurrently for more than 30 days

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Required Documentation

Laboratory Results:  
MedWatch Form:

☐  
☐

Progress Notes:  
Other:

☐  
☒

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

1 year

## Appendix A – Maximum Daily Dosage Limits

Generic Equivalent	Max Daily Dose
DESVENLAFAXINE	400 mg
DULOXETINE	120 mg
LEVOMILNACIPRAN	120 mg
MILNACIPRAN	200 mg
VENLAFAXINE	375 mg
VENLAFAXINE ER	225 mg

## References

- Facts & Comparisons. Serotonin and Norepinephrine Reuptake Inhibitors. Accessed August 10, 2021.